Gain Therapeutics gets FDA IND clearance for rexaceract, targets Phase 2 start in Q3 2026

Gain Therapeutics said on August 11, 2026 that the FDA completed its review of an Investigational New Drug application for rexaceract, with acceptance of the submission paving the way for initiation of Phase 2 clinical development in the U.S., expected during the third quarter of 2026¹. The company noted rexaceract is the first allosteric modulator from its Magellan AI drug discovery platform to receive IND clearance¹.

On the ongoing Phase 1b study, Gain said as of June 30, 2026, 14 of the 16 participants who elected to enroll in the nine-month extension had completed Day 270, with seven crossing the Day 360 mark¹. The company said MDS-UPDRS scores continue to show that patients with high baseline CSF GluSph experience an early and durable response to rexaceract persisting through Day 270 and Day 360, while the overall patient group shows non-progression of Parkinson's symptoms through Day 360¹. Gain said final data from the nine-month extension are expected to be presented in October 2026 at the "International Congress of Parkinson's Disease and Movement Disorders" in Korea¹, and separately listed final results from the Phase 1b study as expected in the fourth quarter of 2026¹.

On its earlier-stage program, Gain said GT-04686 is moving toward IND-enabling studies, with current work focused on optimizing the program and generating data to support that filing¹, and that an initial therapeutic indication for GT-04686 is expected to be selected by year end¹.

On finances, the company reported cash and cash equivalents of $13.1 million as of June 30, 2026, down from $20.8 million as of December 31, 2025¹. Net loss per share was $0.11, basic and diluted, for the second quarter of 2026, compared to $0.19 per share in the same period of 2025¹. The release did not include a specific cash runway statement.